Earnings Call: Q1 2024

May 3, 2024

Quarterly report

Yes. Hello. And first of all, thank you for taking my questions. And my first question actually revolves around the next 22. I mean, as we learned a few weeks ago, I mean, it's a bit delayed. Could you provide more color on the path forward for the next 22 Phase 1 study in 2024? Like once it's up and running, how long do you expect the recruitment to take and the different steps forward? Okay. So yes, that's definitely a relevant question. So but we even though we have a delay and from the approval from the German authorities B farm, We expect to have an approval from them during June, that's the latest, and get started with the first dosing of the patient right after that. There is a slight delay, but we have everything prepared to start it as soon as we get an approval. And as I mentioned, that is what we reasonably have reason to expect during at latest, I'll say, June. So counting on that, we will start dosing, as I mentioned. And we're this is a dose escalation study, and we expect to have results from several of those escalations during second half of this year. So we will be able to get very much relevant data from the study during 2024 and that we believe is quite important. Then we will, from those data, decide how to proceed going into 2025, whether we go into a new Phase 1b study directly or if we do first maybe a preclinical study again to tweak the formulation a bit and then proceed into sort of a final PK study before entering the or the preparation actually for out licensing, I'd say, will start already from when we have the data from this study. But going forward, we don't want to lack in the get any lags, I should say, in the development of the drugs. So we'll plan going forward. And then most likely, the Phase III study will be something that will be done together with a partner. That is how we foresee it. Okay. Very interesting. And I have 2 more questions. One question is about in the report, you have mentioned that you had that you have high hopes for 1 of the collaborations for 1 of the partner projects. And could you elaborate here on what type of data you have generated so far? And also maybe which kind of molecule this project concerns? Because in the past, you have talked about small molecules and asked opportunity in biologics, in antibodies. So I might disappoint you in how much I can say, but because that is, of course, regulated by the agreement we have with the company. But I can say it's one of the larger companies in the world that we're working together with. It's a small molecule. I can mention that as well. And it has an application that's slightly different than just a regular subcu administration. Data. And they've actually also looked at an efficacy parameter and seen that, that works very well as well. But I have a hard time going into exactly what parameter that is. So I'll leave it there. And we still have a good process with that company. And but when if and when a continuation of this will occur, it is hard for me to say at the moment. Okay. Very interesting as well. And then my last question concerns actually the financial part. So maybe it is maybe for Bjorn. So you wrote out on the report that your financial runaway will last for another 12 months from the submission of the report, so basically from now. And my question would be there, if this guidance includes or excludes anticipated revenues from the ongoing partner project, so from the Novo project and or also other projects? Okay. We include the evaluation projects that we're doing with Novo and this other customer and others as well going forward. No major deal included in that scenario. Okay, great. Thank you. Then I'm looking forward to the CMD next week to hear some updates, and thank you very much for today. All right. Thank you, Alexander Kramer. Partners. Bigger Okay. This is from Tuxmik. Tuxmike, you wanted to make mergers of Medias, so Red AXA, SLEPPA IN and 3rdia. Analytikens from Red Ice, Frjadek at Skop and Lixman platform for very bolog some Nongong value at the technical sense for us the agent for bettering of them substance than product, some re adenadaphine, some backbone treatment, border for Milledis plus Sysundum or for MDS. So